Vaccine adjuvants are substances added to vaccines to enhance the body's immune response to the intended antigen. The primary goal is to improve the vaccine's efficacy by promoting a stronger, longer-lasting, and more robust immune reaction. Common adjuvants include aluminum salts (alum), which have been used for decades and are found in various vaccines. Other adjuvants include oil-in-water emulsions, liposomes, and virosomes. These adjuvants often stimulate a more significant production of antibodies and activate immune cells, contributing to a heightened defense against pathogens. Adjuvants play a crucial role in enhancing vaccine effectiveness, especially in situations where a strong immune response is needed, such as in certain populations or against rapidly evolving pathogens. They enable the use of lower vaccine doses while still achieving optimal protection. Research in vaccine adjuvants focuses on understanding their mechanisms of action, optimizing formulations, and ensuring safety. Balancing enhanced immunogenicity with minimal side effects is crucial in developing effective and well-tolerated vaccines for a variety of infectious diseases.
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United Kingdom
Elena Chiappini
University of Florence, ItalySubmit your abstract Today
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Awareness and acceptability of rotavirus vaccine among mothers of under-five children in Gusau and Bungudu communities of Zamfara State, Northwestern Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil